Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methyl-CpG-binding domain protein 6 (MBD6) is a member of the MBD protein family, capable of recognizing methyl-CpG sites on DNA through its conserved methyl-CpG-binding domain[1][2]. The protein has been structurally characterized in *Arabidopsis thaliana*, where it adopts the canonical fold associated with specific recognition of methylated cytosines (CpG dinucleotides) in DNA[1][2]. Its binding affinity to methylated DNA is significantly lower than mammalian MBD homologs due to absence of several key positively charged residues that typically enhance DNA interaction[1][2]. MBD6 exists as a monomer in solution and is implicated in repressing gene expression through binding to methylated DNA, contributing to epigenetic regulation and chromatin localization[1][2]. The functional relevance in human biology or disease is not established, with most available evidence from plant studies—though the domain and sequence conservation are notable.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methyl-CpG-binding domain protein 6 (MBD6).